Corporate News AbbVie in charts: Humira Q3 revenues of $2.23B plunges 37%, Skyrizi, Rinvoq gain Y/Y by Contributor since / Followers 4 weeks ago Tags: ABBV Continue Reading Previous AbbVie lifts outlook again on immunology demand; dividend raisedNext AnaptysBio plunges as Eli Lilly drops arthritis drug from pipeline Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Δ
